Nationwide screening ‘could halve cases of prostate cancer’

Carefully selected men with “low-risk” prostate cancer can safely delay treatment and opt instead for active surveillance, researchers report in the April issue of The Journal of Urology.

Scientists from the German Cancer Research Center report that an improved status of the vitamin was linked to a lower risk of both advanced-stage prostate cancer and high-grade prostate cancer.

UroToday.com – Dr. William Dale and associates reported on the influence of anxiety when a patient with prostate cancer (CaP) and biochemical recurrence (BCR) initiates androgen deprivation therapy (ADT). A total of 67 patients with a mean age of 68 years participated and 70% of these rated their own health as very good or excellent. Data was collected from surveys and medical records.

UroToday.com – In the journal Clinical Chemistry, Dr. Pauliina Helo and the group of Dr. Hans Lilja at Memorial Sloan-Kettering Cancer Center measured circulating tumor cells (CTCs) in prostate cancer patients by the commercially available CellSearch;Veridex assay and compared it to a RT-PCR methodology from their laboratory.

UroToday.com – Although systemic chemotherapy has traditionally been reserved for metastatic prostate cancer (1,2), several investigators have reported on the potential role of incorporating systemic therapy into a multimodal treatment approach in clinically localized high risk prostate cancer (3,4,5,6).

UroToday.com – Dr. William Dale and associates reported on the influence of anxiety when a patient with prostate cancer (CaP) and biochemical recurrence (BCR) initiates androgen deprivation therapy (ADT). A total of 67 patients with a mean age of 68 years participated and 70% of these rated their own health as very good or excellent. Data was collected from surveys and medical records.

UroToday.com – In the journal Clinical Chemistry, Dr. Pauliina Helo and the group of Dr. Hans Lilja at Memorial Sloan-Kettering Cancer Center measured circulating tumor cells (CTCs) in prostate cancer patients by the commercially available CellSearch;Veridex assay and compared it to a RT-PCR methodology from their laboratory. As background, CTCs are under intense investigation as a new and more sensitive marker of disease progression in cancer patients.

UroToday.com – Cytokeratin-positive (CK+) staining cells can be detected in the bone marrow of patients with epithelial cancers but not in control patients. In the online version of the Journal of Clinical Oncology, a group of German researchers investigated whether genetic analysis of disseminated tumor cells (DTCs) at various time points during the disease course correlates with progression and outcomes.

UroToday.com – Although systemic chemotherapy has traditionally been reserved for metastatic prostate cancer (1,2), several investigators have reported on the potential role of incorporating systemic therapy into a multimodal treatment approach in clinically localized high risk prostate cancer (3,4,5,6). We have previously reported on the maximally tolerated dose of weekly docetaxel when administered concurrently with 3-D conformal radiation therapy (7) .